Modified Citrus Pectin Research
2021 Preclinical Study: Modified Citrus Pectin inhibits breast cancer development in mice
2020 Preclinical Study: Modified Citrus Pectin Targets Hypoxia-Induced Galectin-3 in Breast Cancer
2019 Review: The Pleiotropic Effects of Modified Citrus Pectin
2019 Clinical Case Study: Modified Citrus Pectin and Alginate Combo Safely Remove Uranium
2018 Preclinical Study: Modified Citrus Pectin Enhances Radiotherapy Against Prostate Cancer
2016 Preclinical Study: Modified Citrus Pectin Stops Progression of Liver Fibrosis Through Antioxidant Effect, Galectin-3 Inhibitionand Induction of Apoptosis
2011 Preclinical Study: Modified Citrus Pectin Activates Powerful Immune Response
2010 Preclinical Study: Modified Citrus Pectin Inhibits Prostate Cancer
2010 Review: Modified Citrus Pectin Anti-Metastatic Properties
2009 Preclinical Study: Modified Citrus Pectin Binds to Galectin-3
2007 Clinical Study: Modified Citrus Pectin Clinical Benefit in Patients with Advanced Solid Tumors
2006 Clinical Study: The Effect of Modified Citrus Pectin on the Urinary Excretion of Toxic Elements
To Read More, visit: PubMed